415 related articles for article (PubMed ID: 28948496)
21. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.
Lamrani L; Lacout C; Ollivier V; Denis CV; Gardiner E; Ho Tin Noe B; Vainchenker W; Villeval JL; Jandrot-Perrus M
Blood; 2014 Aug; 124(7):1136-45. PubMed ID: 24951423
[TBL] [Abstract][Full Text] [Related]
22. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
[TBL] [Abstract][Full Text] [Related]
23. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
24. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
25. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
[TBL] [Abstract][Full Text] [Related]
26. [Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
Guy A; James C
Med Sci (Paris); 2019; 35(8-9):651-658. PubMed ID: 31532377
[TBL] [Abstract][Full Text] [Related]
27. Thrombotic incidents in patients with myelofibrosis suggest to be independent of
Nikolova D; Radinov A
Folia Med (Plovdiv); 2022 Aug; 64(4):655-660. PubMed ID: 36045460
[TBL] [Abstract][Full Text] [Related]
28. Considerations and recommendations for a new molecular diagnostic algorithm for the myeloproliferative neoplasms.
Haslam K; Langabeer SE
Genet Test Mol Biomarkers; 2014 Nov; 18(11):749-53. PubMed ID: 25259626
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
30. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
31. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
32. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
Andreescu M; Andreescu B
Cureus; 2024 Mar; 16(3):e56008. PubMed ID: 38606222
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
34. Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis of myeloproliferative neoplasms.
Zheng CF; Zhao XX; Chen XH; Liu Z; Wang WJ; Luo M; Ren Y; Wang HW
Int J Lab Hematol; 2021 Aug; 43(4):645-650. PubMed ID: 33973741
[TBL] [Abstract][Full Text] [Related]
35. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
36. [Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].
Xia L; Ding KY; Cai XY; Zhu WB; Liu X; Yang HZ; Wan X; Wu LL; Zeng QS; Wu JS
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):590-3. PubMed ID: 21122317
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of chronic myeloproliferative neoplasias in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
[TBL] [Abstract][Full Text] [Related]
39. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
40. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]